Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.

@article{Johnson2017RealWorldAA,
  title={Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.},
  author={Kristen Marie Johnson and Huanxue Zhou and Feng Lin and John J. Ko and Vivian Herrera},
  journal={Journal of managed care & specialty pharmacy},
  year={2017},
  volume={23 8},
  pages={844-852}
}
BACKGROUND Disease-modifying therapies (DMTs) are indicated to reduce relapse rates and slow disease progression for relapsing-remitting multiple sclerosis (MS) patients when taken as prescribed. Nonadherence or non-persistence in the real-world setting can lead to greater risk for negative clinical outcomes. Although previous research has demonstrated… CONTINUE READING